Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dragonfly Therapeutics
Bristol-Myers Squibb
Replimune Inc.
Myeloid Therapeutics
Bolt Biotherapeutics, Inc.
Compugen Ltd
Eli Lilly and Company
Fondazione per la Medicina Personalizzata
Fate Therapeutics
Fate Therapeutics
Jules Bordet Institute
Celgene